124700-26-1

Basic information

• Product Name: Benzene, 1-fluoro-4-(2-propynyloxy)- (9CI)
• Synonyms: Benzene, 1-fluoro-4-(2-propynyloxy)- (9CI);4-Fluoro-phenyl propargyl ether;1-FLUORO-4-(PROP-2-YN-1-YLOXY)BENZENE(WXFC0574)
• CAS NO: 124700-26-1
• Molecular Formula: C₉H₇FO
• Molecular Weight: 150.1496832
• Product Categories: METHOXY
• Mol File: 124700-26-1.mol

Chemical Properties

• Boiling Point: 218.9±20.0 °C(Predicted)
• Appearance: /
• Density: 1.116±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzene, 1-fluoro-4-(2-propynyloxy)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-fluoro-4-(2-propynyloxy)- (9CI)(124700-26-1)
• EPA Substance Registry System: Benzene, 1-fluoro-4-(2-propynyloxy)- (9CI)(124700-26-1)

Safety Data

• Hazardous Substances Data: 124700-26-1(Hazardous Substances Data)

Upstream product

• 371-41-5 4-Fluorophenol 
• 6921-27-3 dipropargyl ether 
• 107-19-7 propargyl alcohol 
• 2003-82-9 3-bromo-2-propyne 
• 106-96-7 propargyl bromide 

Downstream Products

• 305805-79-2 4-(4-fluorophenoxy)-1-(3,4,5-trimethoxyphenyl)but-2-yn-1-ol 
• 305805-77-0 5-(4-fluorophenoxy)pent-3-yn-2-ol 
• 1029360-97-1 tert-butyl 4-{5-[3-(4-fluorophenoxy)-1-propynyl]-2-pyridyl}-1-piperazine carboxylate 
• 1152593-82-2 5'-{4-[(4-flurophenoxy)methyl]1,2,3-triazol-1-yl}-5'-deoxy-2',3'-O-(1-methylethylidene)uridine 
• 1346019-24-6 2-(3-(4-fluorophenoxy)prop-1-ynyl)aniline 
• 1346018-94-7 1-(2-(3-(4-fluorophenoxy)prop-1-ynyl)phenyl)urea 
• 944904-05-6 6-fluorochroman-3-one 
• 1417919-55-1 (hexacarbonyldicobalt)propargyl para-fluorophenyl ether 
• 371-41-5 4-Fluorophenol 

Relevant articles and documents

1,2,3-Triazole-based kojic acid analogs as potent tyrosinase inhibitors: Design, synthesis and biological evaluation

A series of kojic acid-derived compounds 6a-p bearing aryloxymethyl-1H-1,2,3-triazol-1-yl moiety were designed by modifying primary alcoholic group of kojic acid as tyrosinase inhibitors. The target compounds 6a-p were synthesized via click reaction. All

Alkynylation of cotarnine hydrochloride by Ag(I) acetylenides

1-Organoacetylene derivatives were prepared by reaction of cotarnine hydrochloride with silver organoacetylenides with brief heating in acetonitrile. The structure of one of these, 1-(3 -hydroxypropyn-1-yl)-2-methyl-6,7- methylenedioxy-8-methoxy-1,2,3,4-t

Compound of dipyrrolopyridine structure Preparation method and medical application

The invention discloses a compound with a dipyrrolo-pyridine structure as well as a preparation method and medical application thereof. The compound provided by the invention has obvious inhibitory activity on JAK family proteins, is an effective JAK inhibitor, and has the prospect of being developed into drugs for inhibiting JAK and further treating diseases.

Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines

A series of 1,2,3-triazole-containing Sorafenib analogues, in which the aryl urea moiety of Sorafenib (1) was replaced with a 1,2,3-triazole ring linking a substituted phenoxy fragment, were prepared successfully via Huisgen 1,3-dipolar cycloaddition and

Enantioselective Palladium-Catalyzed Hydrophosphinylation of Allenes with Phosphine Oxides: Access to Chiral Allylic Phosphine Oxides

A Pd-catalyzed hydrophosphinylation of alkyl and aryl-oxyallenes with phosphine oxides has been developed for the efficient and rapid construction of a family of chiral allylic phosphine oxides with a diverse range of functional groups. This methodology was further applied in the facile construction of chiral 2H-chromene and later stage functionalization of cholesterol.

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

Synthesis, characterization, and antiplasmodial efficacy of sulfonamide-appended [1,2,3]-triazoles

A series of benzenesulfonamide-appended [1,2,3]-triazole hybrids was synthesized by using [3 + 2] cycloaddition of primary, secondary, and tertiary sulfonamide azides with various phenoxymethylacetylenes under click reaction conditions. After structural c

Preparation of novel 1,2,3-triazole furocoumarin derivatives via click chemistry and their anti-vitiligo activity

The extracts of Psoralea corylifolia?L. were often used for the repigmentation of leukoderma (vitiligo) in traditional Uygur medicine thousands years ago. Nowadays, its active ingredient, furocoumarins, has been clinically applied since it exhibited stron

Discovery of a novel series of hDHODH inhibitors with anti-pulmonary fibrotic activities

Human dihydroorotate dehydrogenase (hDHODH) is a flavin-dependent enzyme essential to pyrimidine de novo biosynthesis, which serves as an attractive therapeutic target for the treatment of autoimmune disorders. A novel series of hDHODH inhibitors was deve

Synthesis of 3-Organoselenyl-2H-Coumarins from Propargylic Aryl Ethers via Oxidative Radical Cyclization

A metal-free oxidative radical cyclization/selenylation of propargylic aryl ethers with diaryl diselenides was developed. This protocol provided an alternative method to synthesize 3-organoselenyl-2H-coumarins via the formation of C?Se bond, C?C bond, and C=O bond in one step. Moreover, a broad range of functional groups (such as halogen, aldehyde, ketone, cyano, and nitro group) were tolerated. (Figure presented.).